Starting April 21, you’ll be asked to log in or sign up for a free account after viewing 10 content pages each month.
Don’t worry—creating an account is quick and easy, and it comes with added benefits! Once logged in, you’ll not only continue accessing the content you already enjoy, but you’ll also unlock exclusive features like interactive donut plots for variant protein effects and variant impacts across the gene.
Stay tuned for these updates, and thank you for being part of our community!
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | FBXW7 |
Variant | R689W |
Impact List | missense |
Protein Effect | loss of function - predicted |
Gene Variant Descriptions | FBXW7 R689W does not lie within any known functional domains of the Fbxw7 protein (UniProt.org). R689W results in increased levels of phosphorylated Rictor, Akt, Gsk, and p70s6 (PMID: 29963728), and decreased interaction with the T244 degron of Myc in the context of an F-box domain deletion in culture (PMID: 35089787), and therefore, is predicted to lead to a loss of Fbxw7 protein function. |
Associated Drug Resistance | |
Category Variants Paths |
FBXW7 mutant FBXW7 inact mut FBXW7 R689W |
Transcript | NM_033632.3 |
gDNA | chr4:g.152322940G>A |
cDNA | c.2065C>T |
Protein | p.R689W |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
XM_024454124.1 | chr4:g.152322940G>A | c.2065C>T | p.R689W | RefSeq | GRCh38/hg38 |
XM_047415901.1 | chr4:g.152322940G>A | c.2065C>T | p.R689W | RefSeq | GRCh38/hg38 |
XM_024454123.2 | chr4:g.152322940G>A | c.2065C>T | p.R689W | RefSeq | GRCh38/hg38 |
XM_011532083 | chr4:g.152322940G>A | c.2065C>T | p.R689W | RefSeq | GRCh38/hg38 |
XM_047415898.1 | chr4:g.152322940G>A | c.2065C>T | p.R689W | RefSeq | GRCh38/hg38 |
NM_033632.3 | chr4:g.152322940G>A | c.2065C>T | p.R689W | RefSeq | GRCh38/hg38 |
XM_011532084.3 | chr4:g.152322940G>A | c.2065C>T | p.R689W | RefSeq | GRCh38/hg38 |
NM_001349798.1 | chr4:g.152322940G>A | c.2065C>T | p.R689W | RefSeq | GRCh38/hg38 |
XM_047415900.1 | chr4:g.152322940G>A | c.2065C>T | p.R689W | RefSeq | GRCh38/hg38 |
XM_047415897.1 | chr4:g.152322940G>A | c.2065C>T | p.R689W | RefSeq | GRCh38/hg38 |
NM_033632.3 | chr4:g.152322940G>A | c.2065C>T | p.R689W | RefSeq | GRCh38/hg38 |
XM_024454121.1 | chr4:g.152322940G>A | c.2065C>T | p.R689W | RefSeq | GRCh38/hg38 |
XM_011532085.2 | chr4:g.152322940G>A | c.2065C>T | p.R689W | RefSeq | GRCh38/hg38 |
XM_011532085.3 | chr4:g.152322940G>A | c.2065C>T | p.R689W | RefSeq | GRCh38/hg38 |
XM_011532084.2 | chr4:g.152322940G>A | c.2065C>T | p.R689W | RefSeq | GRCh38/hg38 |
XM_024454122.1 | chr4:g.152322940G>A | c.2065C>T | p.R689W | RefSeq | GRCh38/hg38 |
XM_011532084 | chr4:g.152322940G>A | c.2065C>T | p.R689W | RefSeq | GRCh38/hg38 |
XM_047415899.1 | chr4:g.152322940G>A | c.2065C>T | p.R689W | RefSeq | GRCh38/hg38 |
NM_001349798.2 | chr4:g.152322940G>A | c.2065C>T | p.R689W | RefSeq | GRCh38/hg38 |
XM_011532085 | chr4:g.152322940G>A | c.2065C>T | p.R689W | RefSeq | GRCh38/hg38 |
XM_017008362 | chr4:g.152322940G>A | c.2065C>T | p.R689W | RefSeq | GRCh38/hg38 |
NM_033632 | chr4:g.152322940G>A | c.2065C>T | p.R689W | RefSeq | GRCh38/hg38 |
XM_024454123.1 | chr4:g.152322940G>A | c.2065C>T | p.R689W | RefSeq | GRCh38/hg38 |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
FBXW7 inact mut | breast cancer | sensitive | Sirolimus | Preclinical - Cell line xenograft | Actionable | In a preclinical study, breast cancer cells harboring a FBXW7 mutation demonstrated sensitivity to Rapamune (sirolimus) in culture and in cell line xenograft models (PMID: 18787170). | 18787170 |
FBXW7 inact mut | Advanced Solid Tumor | sensitive | Belinostat | Preclinical | Actionable | In a preclinical study, Beleodaq (belinostat) inhibited human cancer cell lines harboring FBXW7 inactivating mutations in culture (PMID: 23274910). | 23274910 |
FBXW7 inact mut | hematologic cancer | sensitive | REC-2282 | Preclinical | Actionable | In a preclinical study, REC-2282 (AR-42) inhibited human hematologic cancer cell lines harboring FBXW7 inactivating mutations in culture (PMID: 23274910). | 23274910 |
FBXW7 inact mut | hematologic cancer | sensitive | Entinostat | Preclinical | Actionable | In a preclinical study, entinostat (MS-275) inhibited cancer cells from advanced solid tumors and hematological cells harboring FBXW7 inactivating mutations in culture (PMID: 23274910). | 23274910 |
FBXW7 inact mut | Advanced Solid Tumor | resistant | Docetaxel | Preclinical | Actionable | In a preclinical study, human cancer cell lines harboring FBXW7 inactivating mutations were resistant to docetaxel in culture (PMID: 23274910). | 23274910 |
FBXW7 inact mut | Advanced Solid Tumor | sensitive | REC-2282 | Preclinical | Actionable | In a preclinical study, REC-2282 (AR-42) inhibited human cancer cell lines harboring FBXW7 inactivating mutations in culture (PMID: 23274910). | 23274910 |
FBXW7 inact mut | Advanced Solid Tumor | sensitive | Entinostat | Preclinical | Actionable | In a preclinical study, entinostat (MS-275) inhibited cancer cells from advanced solid tumors and hematological cells harboring FBXW7 inactivating mutations in culture (PMID: 23274910). | 23274910 |
FBXW7 inact mut | hematologic cancer | sensitive | Belinostat | Preclinical | Actionable | In a preclinical study, Beleodaq (belinostat) inhibited human hematologic cancer cell lines harboring FBXW7 inactivating mutations in culture (PMID: 23274910). | 23274910 |
FBXW7 mutant | Her2-receptor negative breast cancer | predicted - sensitive | LY3039478 | Case Reports/Case Series | Actionable | In a Phase I trial, LY3039478 treatment resulted in partial response lasted 9.5 months in a patient with hormone receptor-positive, Erbb2 (Her2)-negative breast cancer harboring FBXW7 mutation (PMID: 30060061; NCT01695005). | 30060061 |